HME Square, founded in 2020, targets the evolving digital healthcare market with a focus on non-invasive biosignal measurement technology. Their flagship product, GlucoSOUND, aims to revolutionize health management by utilizing photoacoustic technology to measure blood glucose levels non-invasively. This innovative approach aligns well with their slogan, "We listen to your glucose."
Operating from their headquarters in Korea South, HME Square is positioned in the intersection of the Health Care and Medical Devices industries. The company recently secured a KRW4.00B seed investment on 01 December 2023 with support from LB Investment and KB Investments. This financing signals investor confidence in their potential to disrupt traditional glucose monitoring methods.
A skilled team and strategic location in a technologically advanced region further strengthen HME Square's position in the competitive health tech landscape, making them a noteworthy prospect for future investments.